Patents by Inventor David Chantry

David Chantry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMBINATION THERAPY TO TREAT CANCER
    Publication number: 20200368205
    Abstract: This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that consist essentially of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist, to a patient in need thereof.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 26, 2020
    Inventors: Patrice A. LEE, David CHANTRY, Shannon L. WINSKI
  • METHODS AND COMBINATION THERAPY TO TREAT CANCER
    Publication number: 20190216923
    Abstract: This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that consist essentially of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist, to a patient in need thereof.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 18, 2019
    Inventors: Patrice A. Lee, David Chantry, Shannon L. Winski
  • METHODS AND COMBINATION THERAPY TO TREAT CANCER
    Publication number: 20190211102
    Abstract: This invention relates to a method of treating cancer by administering a combination therapy comprising a combination of CSF-1R inhibitor, which is ARRY-382 or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist, to a patient in need thereof.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 11, 2019
    Inventors: Patrice A. Lee, David Chantry, Shannon L. Winski
  • Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances and uses thereof
    Publication number: 20060057112
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated “Macrophage Derived Chemokine” (MDC), and polypeptide fragments and analogs thereof. Also provided are materials and methods for the recombinant or synthetic production of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity.
    Type: Application
    Filed: October 28, 2005
    Publication date: March 16, 2006
    Applicant: ICOS CORPORATION
    Inventors: Patrick Gray, David Chantry, Michael Deeley, Carol Raport, Ronald Godiska
  • Therapeutic uses for MDC and MDC antagonists
    Publication number: 20050238647
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.
    Type: Application
    Filed: April 6, 2004
    Publication date: October 27, 2005
    Applicant: ICOS CORPORATION
    Inventors: Patrick Gray, David Chantry, Michael Deeley
  • G protein-coupled receptor kinase GRK6
    Patent number: 5591618
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding the novel G protein-coupled receptor kinase designated GRK6. Also provided by the invention are methods and materials for the recombinant production of GRK6 enzyme and methods for identifying compounds which modulate the protein kinase activity of GRK6.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 7, 1997
    Assignee: ICOS Corporation
    Inventors: David Chantry, Patrick W. Gray, Merl F. Hoekstra
  • G protein-coupled receptor kinase GRK6
    Patent number: 5532151
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding the novel G protein-coupled receptor kinase designated GRK6. Also provided by the invention are methods and materials for the recombinant production of GRK6 enzyme and methods for identifying compounds which modulate the protein kinase activity of GRK6.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: July 2, 1996
    Assignee: ICOS Corporation
    Inventors: David Chantry, Patrick W. Gray, Merl F. Hoekstra